Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center - PubMed

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center - PubMed

Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center

Katya Losk 1 2, Rachel A Freedman 3 4 5, Alison Laws 6, Olga Kantor 6, Elizabeth A Mittendorf 4 5 6, Zhenying Tan-Wasielewski 7, Lorenzo Trippa 7, Nancy U Lin 3 4 5, Eric P Winer 3 4 5, Tari A King 4 5 6

Affiliations 

• PMID: 32939592
 
• DOI: 10.1007/s10549-020-05931-9

Abstract

Purpose: In 2016, we initiated standardized "reflex" Oncotype DX Recurrence Score (RS) testing for patients ≤ 65 years with pT1-2N0-1 HR+/HER2- breast cancer. Here, we examine RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1 breast cancer.

Methods: Patients with stage I-III HR+/HER2- pN1 breast cancer treated with upfront surgery from February 2016 to March 2019 were identified. Clinical characteristics were compared between patients meeting reflex RS testing criteria, those with RS ordered outside of reflex criteria, and those without RS testing. RS was categorized as low (< 18), intermediate (18-30), and high (≥ 31). Multivariate logistic regression was performed to identify factors associated with adjuvant chemotherapy receipt. We examined 3-year recurrence-free survival (RFS) and overall survival (OS) stratified by chemotherapy use.

Results: We identified 347 HR+/HER2- pN1 patients; 272 (78.4%) received RS testing, and 194 (71.3%) met reflex criteria. RS was < 18 in 164 (61.4%) patients, 18-30 in 89 (32.7%) patients, and ≥ 31 in 16 (5.9%) patients. On multivariate analysis, RS < 18 (OR 0.47, 95% CI 0.24-0.92) was associated with lower odds of chemotherapy use, whereas presence of lymphovascular invasion (OR 1.77, 95% CI 1.03-3.07) and lobular subtype (OR 2.40, 95% CI 1.21-4.78) were associated with higher odds. No differences in 3-year RFS (p = 0.97) or OS (p = 0.19) based on chemotherapy receipt were observed.

Conclusion: Most RS-tested HR+/HER2- pN1 patients at our center had low genomic risk. A low RS independently influenced chemotherapy omission and in RS-tested patients, short-term outcomes were excellent. Our study demonstrates increased use of RS in guiding adjuvant treatment decisions in node-positive disease.

Keywords: Adjuvant chemotherapy; Lymph node-positive breast cancer; Oncotype DX recurrence score.

Similar articles

• Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.

  Medical Advisory Secretariat.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1.PMID: 23074401 Free PMC article.
• The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.

  Thibodeau S, Voutsadakis IA.Eur J Breast Health. 2019 Jul 1;15(3):163-170. doi: 10.5152/ejbh.2019.4901. eCollection 2019 Jul.PMID: 31312792 Free PMC article.
• Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.

  Natsuhara KH, Losk K, King TA, Lin NU, Camuso K, Golshan M, Pochebit S, Brock JE, Bunnell CA, Freedman RA.Oncologist. 2019 May;24(5):595-602. doi: 10.1634/theoncologist.2018-0154. Epub 2018 Aug 3.PMID: 30076279 Free PMC article.
• Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.

  Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, Ryu HS, Kim WH, Chang JM, Cho N, Moon WK, Cheon GJ.Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1574-84. doi: 10.1007/s00259-016-3418-1. Epub 2016 May 21.PMID: 27209424
• Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.

  Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS.NPJ Breast Cancer. 2018 Aug 20;4:27. doi: 10.1038/s41523-018-0082-6. eCollection 2018.PMID: 30155517 Free PMC article. Review.